The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Justin speaks with Nicky Agahari, founder and CEO of Australis Scientific, one of Australia’s most exciting emerging med-tech ...

ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3.

Background It is suggested that late initiation of toilet training contributes to functional gastrointestinal disorders in children. This study aims to evaluate if assisted infant toilet training can ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Gene Holdings Inc. remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid. Learn more about ENGN stock here.

Holly Robinson Peete and Rodney Peete are turning the spotlight on a shared, often-private struggle: Overactive Bladder ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Over the decades, L.A. has become known for its wildly fun stock of iconic billboards. Angelenos called into LAist 89.3’s ...

Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties : As we prepare to end 2025, we would like to provide you with this open letter summarizing our ...

The FDA approved Johnson & Johnson ’s Darzalex for smoldering multiple myeloma. Thermo Fisher Scientific received 510 (k) clearance in the U.S. for its Exent System to aid in the diagnosis of multiple ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products b ...